Tenaya Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
FY Revenue (est.)
$4Mnext fiscal year
FY EPS (est.)
-$0.46next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| TN-201 MyPEAK-1 Phase 1b/2 Trial Additional Long-Term Data (Cohort 1 & 2) | 15 Nov 2026 |
| TN-401 RIDGE-1 Phase 1b/2 Trial Regulatory Alignment Update | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
TN-201 Left Ventricular Mass Index (LVMI) Reduction QuarterlyTarget: Consistent reduction in LVMI across all treated cohorts to demonstrate cardiac remodeling
TN-401 Arrhythmia Burden Reduction (PVC Count) Quarterly67Target: Sustained reduction in PVC burden and elimination of non-sustained ventricular tachycardia (NSVT) episodes
Cash Runway (Months of Funding) QuarterlyTarget: Maintain cash runway extending into the second half of 2027
Watch Items
- Regulatory alignment with the FDA and EMA on pivotal study designs for TN-201 and TN-401Trigger: Receipt of official regulatory feedback or protocol agreementAction: Initiate registrational Phase 2/3 trials and finalize commercial manufacturing scale-up plans
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business days (compliance deadline July 27, 2026)Action: Regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days, or evaluate a reverse stock split
- TN-301 Clinical Trial Initiation in PatientsTrigger: First patient dosed in clinical trials for HFpEF or Duchenne Muscular Dystrophy (DMD)Action: Review initial safety, tolerability, and proof-of-activity biomarker data
Research as of 20 Jun 2026